BACK

Shane  Moriarty

Shane Moriarty

Associate

New York Office  |  shane.moriarty@torreya.com   |   212.257.6032

Shane Moriarty is an Associate at Torreya in the Capital Markets Group. He provides transaction support across different sectors in the healthcare industry.

Prior to joining Torreya in 2019, Shane worked as a Financial Analyst at PureTech Health, focusing on operations at both a corporate and affiliate level, as well as affiliate valuations and equity financings.

Shane received an B.A. in Economics from Harvard University in 2017.

Selected Transactions

Vectura
Management buyout of
Skyepharma SAS
June 2021
binx health
Series E equity financing
Series E
$104 million
May 2021
Indegene
Equity investment from
Carlyle and Brighton Park
$200 million
February 2021
SparingVision
Equity Financing Round
None
€44.5 million
October 2020
Mission Pharmacal
Debt financing by
Gordon Brothers
$57.5 million
February 2020
Global Medical Education
Acquired by
Clinical Education Alliance
October 2020
Oncosec Medical
Co-advisor on direct public offering
None
$15 million
August 2020
Oncosec Medical
Strategic investment from
China Grand and SirTex
$30 million
February 2020